MetaCap

ABVC BioPharma (ABVC) vs CervoMed (CRVO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ABVC BioPharma (ABVC) has outperformed CervoMed (CRVO) over the past year, losing 67.8% versus a loss of 83.6%. Over five years, CRVO leads with a -95.0% price change compared with -97.3% for ABVC. ABVC BioPharma is the larger company by market cap ($23.4 million vs $22.1 million), about 1.1 times the size.

CervoMed converts more of its revenue into profit, with a net margin of -673.1% versus -2671.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABVC-67.80%CRVO-83.56%
+17%-37%-90%
Nov 21, 20251 yearNov 20, 2026
ABVC-97.37%CRVO-95.01%
+20%-42%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABVC versus CRVO key metrics
MetricABVCCRVO
Share price$0.8663$1.46
Market cap$23.37M$22.09M
1-day change-1.56%+9.77%
YTD return-59.33%-81.52%
1-year return-67.80%-83.56%
5-year return-97.29%-95.01%
EPS (TTM)$-0.20$-2.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$296.00K$4.01M
Revenue growth (YoY)-41.91%-58.86%
Net income (latest FY)$-7.91M$-26.97M
Operating margin-2415.97%-706.22%
Net margin-2671.81%-673.06%
52-week high$2.87$10.00
52-week low$0.707$1.27
Distance from 52-week high-69.82%-85.40%
Analyst consensus—strong_buy
Avg. price target upside—+954.79%
Average volume81.92K489.10K
Shares outstanding26.98M15.13M
Employees1615
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ABVC has outperformed CRVO by 15.8 percentage points over the past year.
  • CervoMed is more profitable, keeping -673.1 cents of every revenue dollar as net income versus -2671.8 cents for ABVC BioPharma.
  • ABVC BioPharma grew revenue faster in its latest fiscal year (-41.91% vs -58.86%).

About ABVC BioPharma

ABVC stock →

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

About CervoMed

CRVO stock →

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

ABVC vs CRVO FAQ

Which is bigger, ABVC BioPharma or CervoMed?

ABVC BioPharma (ABVC) is larger, with a market capitalization of $23.37M compared with $22.09M for CervoMed (CRVO).

Which stock has performed better over the past year, ABVC or CRVO?

ABVC returned -67.80% over the past 12 months, compared with -83.56% for CRVO (price return, excluding dividends). Past performance does not predict future results.

Are ABVC BioPharma and CervoMed in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons